📰 Available Methods News
Available Methods News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Available Methods. Real-time updates on events, politics, business and more.
February 19, 2024
First EGFR inhibitor and targeted treatment to demonstrate progression-free survival benefit in Stage III setting ...
January 17, 2024
On December 20, 2023, the Federal Trade Commission (FTC) published a Notice of Proposed Rulemaking (Proposed Rule) seeking to update the Children’s Online Privacy Protection Act...
October 16, 2023
WILMINGTON, Del.--(BUSINESS WIRE)--Oct 16, 2023--
September 11, 2023
Combination reduced the risk of disease progression by 38% versus TAGRISSO monotherapy, the current 1st-line global standard of care ...
May 17, 2023
* Results support potential for a new treatment option that builds on the benefit of first-line standard of care Tagrisso monotherapy Positive high-level results from the FLAURA2 Phase III trial... | May 17, 2023
May 17, 2023
Results support potential for a new treatment option that builds on the benefit of first-line standard of care TAGRISSO monotherapy ... | May 17, 2023
September 11, 2022
Nearly three in four patients treated with adjuvant TAGRISSO were alive and disease-free at four years Exploratory results showed TAGRISSO also reduced the risk of disease recurrence in the brain or spinal cord by 76% in patients with Stage II-IIIA disease
August 25, 2022
Investegate announcements from AstraZeneca PLC, Tagrisso approved in Japan for early lung cancer
March 7, 2022
07.03.2022 - HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 07, 2022 (GLOBE NEWSWIRE) - (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has received a US$15 million milestone payment from AstraZeneca PLC (“AstraZeneca”) ...